Johnson & Johnson stock has delivered a 66.6% gain over the past 5 years, yet current checks flag a mixed picture on value, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market multiples suggest pricing is closer to fair.

• A 66.6% return over 5 years signals that long term holders have already seen substantial value creation, which raises the bar for any new upside case.
• Ambitious growth plans in oncology and other specialty medicines can support higher cash flow expectations, while ongoing talc and related litigation remains a key risk that may weigh on how investors price the stock.
• On Simply Wall St's broader checks, Johnson & Johnson screens as undervalued in 3 out of 6 valuation tests, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Johnson & Johnson's current share price around US$248.82 still leaves enough margin between market price and intrinsic value to appeal to new money coming in.

Is Johnson & Johnson a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model values a company by projecting the cash it can return to shareholders over time and discounting those flows back to today. For Johnson & Johnson, the model uses latest twelve month free cash flow of about $17.1b and assumes cash flows continue growing from this base, consistent with a mature but expanding pharmaceuticals and MedTech business.

On these cash flow assumptions, the DCF output points to an estimated intrinsic value of about $378 per share, compared with the current share price around $248.82. That implies the stock screens roughly 34.1% undervalued on this model. The recent appellate court decision upholding a $45 million talc verdict helps explain why some investors may still be hesitant, even though the cash flow based value sits well above where the market is pricing Johnson & Johnson today.

On this Discounted Cash Flow view, Johnson & Johnson stock currently appears undervalued relative to its projected cash generation according to this model.

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 34.1%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Is Johnson & Johnson Fairly Priced on Earnings?

The P/E ratio is a useful way to look at Johnson & Johnson because earnings are a key focus for many investors in large, established healthcare companies. Johnson & Johnson currently trades on a P/E of about 28.5x, which is close to the modelled fair P/E of 28.8x that reflects its size, margins, industry profile and risk factors.

This P/E is slightly above the peer average of 27.6x and sits well above the broader Pharmaceuticals industry average of 14.9x, which is common for larger, diversified groups in the sector. The small gap between the current multiple and the 28.8x fair ratio suggests that, on earnings, Johnson & Johnson is pricing in neither a clear discount nor a clear premium relative to what this framework would imply.

On the P/E multiple, Johnson & Johnson stock appears roughly fairly valued against its earnings power.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Johnson & Johnson's mixed valuation signals leave off by spelling out which assumptions about its future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative sits on the Community page and sets out fair value as a thesis about Johnson & Johnson's business that you can watch over time, rather than a one off snapshot.

The community is split on Johnson & Johnson, with one camp focused on future drug cycles and another emphasizing that the current set up already prices in much of the quality story.

Bull case: roughly fairly valued

"The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices, potentially increasing operational efficiency and future earnings..."

Bear case: roughly fairly valued

"At ~22× earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow..."

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

The Bottom Line

For Johnson & Johnson, the Discounted Cash Flow (DCF) intrinsic value estimate sits well above the current share price, while the P/E based view sits closer to about right, so valuation signals are mixed rather than one way. The gap largely comes down to how you weigh long term cash flow potential against current sentiment and peer pricing on earnings. With broader checks landing in the middle, the key question is whether the current discount reflects temporary caution around litigation and execution, or whether the market is correctly pricing those risks into Johnson & Johnson's stock.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.